Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

estradiol

×

Overview

What is EstroGel?

EstroGel (estradiol gel) contains 0.06 percent estradiol in an absorptive hydroalcoholic gel base for topical application. It is a clear, colorless gel, which is odorless when dry. One pump depression of EstroGel delivers 1.25 g of gel containing 0.75 mg estradiol.

Estradiol is a white crystalline powder, chemically described as estra‑1,3,5(10)-triene-3,17β-diol. It has an empirical formula of CHO and molecular weight of 272.39. The structural formula is:

The active component of the gel is estradiol. The remaining components of the gel (purified water, alcohol, triethanolamine and carbomer 934P) are pharmacologically inactive.



What does EstroGel look like?



What are the available doses of EstroGel?

1 pump depression of EstroGel 0.06% delivers 1.25 g of gel containing 0.75 mg estradiol ()

What should I talk to my health care provider before I take EstroGel?

How should I use EstroGel?

Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be considered to reduce the risk of endometrial cancer. A woman without a uterus does not need progestin. In some cases, however, hysterectomized women with a history of endometriosis may need a progestin .

Use of estrogen-alone or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be reevaluated periodically as clinically appropriate to determine if treatment is still necessary.


What interacts with EstroGel?

Sorry No Records found


What are the warnings of EstroGel?

Sorry No Records found


What are the precautions of EstroGel?

Sorry No Records found


What are the side effects of EstroGel?

Sorry No records found


What should I look out for while using EstroGel?

EstroGel is contraindicated in women with any of the following conditions:


What might happen if I take too much EstroGel?

Overdosage of estrogen may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness and fatigue, and withdrawal bleeding may occur in women. Treatment of overdose consists of discontinuation of EstroGel together with institution of appropriate symptomatic care.


How should I store and handle EstroGel?

Store at 20 to 25C (68 to 77F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Keep tightly closed (protect from moisture). Protect from light.Hydroxyzine Hydrochloride Tablets USP, 25 mg are available as 10/32", Green round biconvex film-coated tablets debossed above on one side and plain on the other side, Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6617-61Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6618-61Hydroxyzine Hydrochloride Tablets USP, 50 mg are available as 11/32", Yellow round biconvex film-coated tablets, debossed above on one side and plain on the other side, packaged in bottles of 100’s, 500’s and 1000’s.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured by:Epic Pharma, LLCLaurelton, NY 11413Manufactured in USADistributed By:MAJOR® PHARMACEUTICALS17177 N Laurel Park Dr., Suite 233Livonia, MI 48152Refer to package label for Distributor's NDC Number Revised October 2016MF159REV10/16OE1518Hydroxyzine Hydrochloride Tablets USP, 25 mg are available as 10/32", Green round biconvex film-coated tablets debossed above on one side and plain on the other side, Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6617-61Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6618-61Hydroxyzine Hydrochloride Tablets USP, 50 mg are available as 11/32", Yellow round biconvex film-coated tablets, debossed above on one side and plain on the other side, packaged in bottles of 100’s, 500’s and 1000’s.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured by:Epic Pharma, LLCLaurelton, NY 11413Manufactured in USADistributed By:MAJOR® PHARMACEUTICALS17177 N Laurel Park Dr., Suite 233Livonia, MI 48152Refer to package label for Distributor's NDC Number Revised October 2016MF159REV10/16OE1518Hydroxyzine Hydrochloride Tablets USP, 25 mg are available as 10/32", Green round biconvex film-coated tablets debossed above on one side and plain on the other side, Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6617-61Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6618-61Hydroxyzine Hydrochloride Tablets USP, 50 mg are available as 11/32", Yellow round biconvex film-coated tablets, debossed above on one side and plain on the other side, packaged in bottles of 100’s, 500’s and 1000’s.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured by:Epic Pharma, LLCLaurelton, NY 11413Manufactured in USADistributed By:MAJOR® PHARMACEUTICALS17177 N Laurel Park Dr., Suite 233Livonia, MI 48152Refer to package label for Distributor's NDC Number Revised October 2016MF159REV10/16OE1518Hydroxyzine Hydrochloride Tablets USP, 25 mg are available as 10/32", Green round biconvex film-coated tablets debossed above on one side and plain on the other side, Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6617-61Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6618-61Hydroxyzine Hydrochloride Tablets USP, 50 mg are available as 11/32", Yellow round biconvex film-coated tablets, debossed above on one side and plain on the other side, packaged in bottles of 100’s, 500’s and 1000’s.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured by:Epic Pharma, LLCLaurelton, NY 11413Manufactured in USADistributed By:MAJOR® PHARMACEUTICALS17177 N Laurel Park Dr., Suite 233Livonia, MI 48152Refer to package label for Distributor's NDC Number Revised October 2016MF159REV10/16OE1518Hydroxyzine Hydrochloride Tablets USP, 25 mg are available as 10/32", Green round biconvex film-coated tablets debossed above on one side and plain on the other side, Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6617-61Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6618-61Hydroxyzine Hydrochloride Tablets USP, 50 mg are available as 11/32", Yellow round biconvex film-coated tablets, debossed above on one side and plain on the other side, packaged in bottles of 100’s, 500’s and 1000’s.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured by:Epic Pharma, LLCLaurelton, NY 11413Manufactured in USADistributed By:MAJOR® PHARMACEUTICALS17177 N Laurel Park Dr., Suite 233Livonia, MI 48152Refer to package label for Distributor's NDC Number Revised October 2016MF159REV10/16OE1518Hydroxyzine Hydrochloride Tablets USP, 25 mg are available as 10/32", Green round biconvex film-coated tablets debossed above on one side and plain on the other side, Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6617-61Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6618-61Hydroxyzine Hydrochloride Tablets USP, 50 mg are available as 11/32", Yellow round biconvex film-coated tablets, debossed above on one side and plain on the other side, packaged in bottles of 100’s, 500’s and 1000’s.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured by:Epic Pharma, LLCLaurelton, NY 11413Manufactured in USADistributed By:MAJOR® PHARMACEUTICALS17177 N Laurel Park Dr., Suite 233Livonia, MI 48152Refer to package label for Distributor's NDC Number Revised October 2016MF159REV10/16OE1518Hydroxyzine Hydrochloride Tablets USP, 25 mg are available as 10/32", Green round biconvex film-coated tablets debossed above on one side and plain on the other side, Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6617-61Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6618-61Hydroxyzine Hydrochloride Tablets USP, 50 mg are available as 11/32", Yellow round biconvex film-coated tablets, debossed above on one side and plain on the other side, packaged in bottles of 100’s, 500’s and 1000’s.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured by:Epic Pharma, LLCLaurelton, NY 11413Manufactured in USADistributed By:MAJOR® PHARMACEUTICALS17177 N Laurel Park Dr., Suite 233Livonia, MI 48152Refer to package label for Distributor's NDC Number Revised October 2016MF159REV10/16OE1518Hydroxyzine Hydrochloride Tablets USP, 25 mg are available as 10/32", Green round biconvex film-coated tablets debossed above on one side and plain on the other side, Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6617-61Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6618-61Hydroxyzine Hydrochloride Tablets USP, 50 mg are available as 11/32", Yellow round biconvex film-coated tablets, debossed above on one side and plain on the other side, packaged in bottles of 100’s, 500’s and 1000’s.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured by:Epic Pharma, LLCLaurelton, NY 11413Manufactured in USADistributed By:MAJOR® PHARMACEUTICALS17177 N Laurel Park Dr., Suite 233Livonia, MI 48152Refer to package label for Distributor's NDC Number Revised October 2016MF159REV10/16OE1518Hydroxyzine Hydrochloride Tablets USP, 25 mg are available as 10/32", Green round biconvex film-coated tablets debossed above on one side and plain on the other side, Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6617-61Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6618-61Hydroxyzine Hydrochloride Tablets USP, 50 mg are available as 11/32", Yellow round biconvex film-coated tablets, debossed above on one side and plain on the other side, packaged in bottles of 100’s, 500’s and 1000’s.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured by:Epic Pharma, LLCLaurelton, NY 11413Manufactured in USADistributed By:MAJOR® PHARMACEUTICALS17177 N Laurel Park Dr., Suite 233Livonia, MI 48152Refer to package label for Distributor's NDC Number Revised October 2016MF159REV10/16OE1518Hydroxyzine Hydrochloride Tablets USP, 25 mg are available as 10/32", Green round biconvex film-coated tablets debossed above on one side and plain on the other side, Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6617-61Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6618-61Hydroxyzine Hydrochloride Tablets USP, 50 mg are available as 11/32", Yellow round biconvex film-coated tablets, debossed above on one side and plain on the other side, packaged in bottles of 100’s, 500’s and 1000’s.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured by:Epic Pharma, LLCLaurelton, NY 11413Manufactured in USADistributed By:MAJOR® PHARMACEUTICALS17177 N Laurel Park Dr., Suite 233Livonia, MI 48152Refer to package label for Distributor's NDC Number Revised October 2016MF159REV10/16OE1518Hydroxyzine Hydrochloride Tablets USP, 25 mg are available as 10/32", Green round biconvex film-coated tablets debossed above on one side and plain on the other side, Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6617-61Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6618-61Hydroxyzine Hydrochloride Tablets USP, 50 mg are available as 11/32", Yellow round biconvex film-coated tablets, debossed above on one side and plain on the other side, packaged in bottles of 100’s, 500’s and 1000’s.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured by:Epic Pharma, LLCLaurelton, NY 11413Manufactured in USADistributed By:MAJOR® PHARMACEUTICALS17177 N Laurel Park Dr., Suite 233Livonia, MI 48152Refer to package label for Distributor's NDC Number Revised October 2016MF159REV10/16OE1518Hydroxyzine Hydrochloride Tablets USP, 25 mg are available as 10/32", Green round biconvex film-coated tablets debossed above on one side and plain on the other side, Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6617-61Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6618-61Hydroxyzine Hydrochloride Tablets USP, 50 mg are available as 11/32", Yellow round biconvex film-coated tablets, debossed above on one side and plain on the other side, packaged in bottles of 100’s, 500’s and 1000’s.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured by:Epic Pharma, LLCLaurelton, NY 11413Manufactured in USADistributed By:MAJOR® PHARMACEUTICALS17177 N Laurel Park Dr., Suite 233Livonia, MI 48152Refer to package label for Distributor's NDC Number Revised October 2016MF159REV10/16OE1518Hydroxyzine Hydrochloride Tablets USP, 25 mg are available as 10/32", Green round biconvex film-coated tablets debossed above on one side and plain on the other side, Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6617-61Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6618-61Hydroxyzine Hydrochloride Tablets USP, 50 mg are available as 11/32", Yellow round biconvex film-coated tablets, debossed above on one side and plain on the other side, packaged in bottles of 100’s, 500’s and 1000’s.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured by:Epic Pharma, LLCLaurelton, NY 11413Manufactured in USADistributed By:MAJOR® PHARMACEUTICALS17177 N Laurel Park Dr., Suite 233Livonia, MI 48152Refer to package label for Distributor's NDC Number Revised October 2016MF159REV10/16OE1518Hydroxyzine Hydrochloride Tablets USP, 25 mg are available as 10/32", Green round biconvex film-coated tablets debossed above on one side and plain on the other side, Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6617-61Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6618-61Hydroxyzine Hydrochloride Tablets USP, 50 mg are available as 11/32", Yellow round biconvex film-coated tablets, debossed above on one side and plain on the other side, packaged in bottles of 100’s, 500’s and 1000’s.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured by:Epic Pharma, LLCLaurelton, NY 11413Manufactured in USADistributed By:MAJOR® PHARMACEUTICALS17177 N Laurel Park Dr., Suite 233Livonia, MI 48152Refer to package label for Distributor's NDC Number Revised October 2016MF159REV10/16OE1518Hydroxyzine Hydrochloride Tablets USP, 25 mg are available as 10/32", Green round biconvex film-coated tablets debossed above on one side and plain on the other side, Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6617-61Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6618-61Hydroxyzine Hydrochloride Tablets USP, 50 mg are available as 11/32", Yellow round biconvex film-coated tablets, debossed above on one side and plain on the other side, packaged in bottles of 100’s, 500’s and 1000’s.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured by:Epic Pharma, LLCLaurelton, NY 11413Manufactured in USADistributed By:MAJOR® PHARMACEUTICALS17177 N Laurel Park Dr., Suite 233Livonia, MI 48152Refer to package label for Distributor's NDC Number Revised October 2016MF159REV10/16OE1518Hydroxyzine Hydrochloride Tablets USP, 25 mg are available as 10/32", Green round biconvex film-coated tablets debossed above on one side and plain on the other side, Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6617-61Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6618-61Hydroxyzine Hydrochloride Tablets USP, 50 mg are available as 11/32", Yellow round biconvex film-coated tablets, debossed above on one side and plain on the other side, packaged in bottles of 100’s, 500’s and 1000’s.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured by:Epic Pharma, LLCLaurelton, NY 11413Manufactured in USADistributed By:MAJOR® PHARMACEUTICALS17177 N Laurel Park Dr., Suite 233Livonia, MI 48152Refer to package label for Distributor's NDC Number Revised October 2016MF159REV10/16OE1518Hydroxyzine Hydrochloride Tablets USP, 25 mg are available as 10/32", Green round biconvex film-coated tablets debossed above on one side and plain on the other side, Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6617-61Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6618-61Hydroxyzine Hydrochloride Tablets USP, 50 mg are available as 11/32", Yellow round biconvex film-coated tablets, debossed above on one side and plain on the other side, packaged in bottles of 100’s, 500’s and 1000’s.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured by:Epic Pharma, LLCLaurelton, NY 11413Manufactured in USADistributed By:MAJOR® PHARMACEUTICALS17177 N Laurel Park Dr., Suite 233Livonia, MI 48152Refer to package label for Distributor's NDC Number Revised October 2016MF159REV10/16OE1518Hydroxyzine Hydrochloride Tablets USP, 25 mg are available as 10/32", Green round biconvex film-coated tablets debossed above on one side and plain on the other side, Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6617-61Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6618-61Hydroxyzine Hydrochloride Tablets USP, 50 mg are available as 11/32", Yellow round biconvex film-coated tablets, debossed above on one side and plain on the other side, packaged in bottles of 100’s, 500’s and 1000’s.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured by:Epic Pharma, LLCLaurelton, NY 11413Manufactured in USADistributed By:MAJOR® PHARMACEUTICALS17177 N Laurel Park Dr., Suite 233Livonia, MI 48152Refer to package label for Distributor's NDC Number Revised October 2016MF159REV10/16OE1518Hydroxyzine Hydrochloride Tablets USP, 25 mg are available as 10/32", Green round biconvex film-coated tablets debossed above on one side and plain on the other side, Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6617-61Carton of 100 tablets (10 tablets each blister pack x 10) NDC 0904-6618-61Hydroxyzine Hydrochloride Tablets USP, 50 mg are available as 11/32", Yellow round biconvex film-coated tablets, debossed above on one side and plain on the other side, packaged in bottles of 100’s, 500’s and 1000’s.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Manufactured by:Epic Pharma, LLCLaurelton, NY 11413Manufactured in USADistributed By:MAJOR® PHARMACEUTICALS17177 N Laurel Park Dr., Suite 233Livonia, MI 48152Refer to package label for Distributor's NDC Number Revised October 2016MF159REV10/16OE1518


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level.

The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate‑conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women.

Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue.

Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and FSH through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.

Non-Clinical Toxicology
EstroGel is contraindicated in women with any of the following conditions:

Oral metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other coumarin anticoagulants, resulting in a prolongation of prothrombin time. This possible drug interaction should be considered when metronidazole vaginal gel is prescribed for patients on this type of anticoagulant therapy.

In patients stabilized on relatively high doses of lithium, short-term oral metronidazole therapy has been associated with elevation of serum lithium levels and, in a few cases, signs of lithium toxicity.

Use of cimetidine with oral metronidazole may prolong the half-life and decrease plasma clearance of metronidazole.

An increased risk of stroke and DVT has been reported with estrogen-alone therapy. An increased risk of PE, DVT, stroke and MI has been reported with estrogen plus progestin therapy. Should any of these occur or be suspected, estrogen with or without progestin therapy should be discontinued immediately.

Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately.

In the WHI estrogen-alone substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years). The increase in risk was demonstrated in year 1 and persisted . Should a stroke occur or be suspected, estrogen-alone therapy should be discontinued immediately.

Subgroup analysis of women 50 to 59 years of age suggest no increased risk of stroke for those women receiving CE (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years).

In the WHI estrogen plus progestin substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women in the same age group receiving placebo (33 versus 25 per 10,000 women-years) . The increase in risk was demonstrated after the first year and persisted. Should a stroke occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.

In the WHI estrogen-alone substudy, no overall effect on coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD death) was reported in women receiving estrogen-alone compared to placebo

Subgroup analyses of women 50 to 59 years of age suggest a statistically non-significant reduction in CHD events (CE [0.625 mg]-alone compared to placebo) in women with less than 10 years since menopause (8 versus 16 per 10,000 women-years).

In the WHI estrogen plus progestin substudy, there was a statistically non-significant increased risk of CHD events reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women-years). An increase in relative risk was demonstrated in year 1, and a trend toward decreasing relative risk was reported in years 2 through 5

In postmenopausal women with documented heart disease (n = 2,763, average 66.7 years of age), in a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study [HERS]), treatment with daily CE (0.625 mg) plus MPA (2.5 mg) demonstrated no cardiovascular benefit. During an average follow-up of 4.1 years, treatment with CE plus MPA did not reduce the overall rate of CHD events in postmenopausal women with established coronary heart disease. There were more CHD events in the CE plus MPA-treated group than in the placebo group in year 1, but not during the subsequent years. Two thousand, three hundred twenty-one (2,321) women from the original HERS trial agreed to participate in an open-label extension of HERS, HERS II. Average follow‑up in HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were comparable among women in the CE plus MPA group and the placebo group in HERS, HERS II, and overall.

In the WHI estrogen-alone substudy, the risk of VTE (DVT and PE) was increased for women receiving daily CE (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women‑years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years). The increase in VTE risk was demonstrated during the first 2 years Should a VTE occur or be suspected, estrogen-alone therapy should be discontinued immediately.

In the WHI estrogen plus progestin substudy, a statistically significant 2‑fold greater rate of VTE was reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women‑years). Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also demonstrated. The increase in VTE risk was demonstrated during the first year and persisted . Should a VTE occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.

If feasible, estrogens should be discontinued at least 4 to 6 weeks before any surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization.

The following serious adverse reactions are discussed elsewhere in the labeling:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).